Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurocognitive Disorders × XENP 1595 × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Tauopathies 2 Neurodegenerative Diseases 2 Nervous System Diseases 2 Mental Disorders 2 Inflammation 2 Dementia 2 Central Nervous System Diseases 2 Brain Diseases 2 Alzheimer Disease 2 Neurocognitive Disorders 1 Cognitive Dysfunction 1

Interventions

XENP 1595 1 Sodium Chloride 1 Saline Solution 1 Dexmedetomidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡